Since October 1, 2025, organizations applying to the National Institutes of Health for a commercial patent license on an NIH-owned invention have had to submit an access plan alongside their license application – a written description of how they intend to promote patient access to any drug, biologic, or medical device that results from the licensed technology. The requirement comes from NIH’s Intramural Research Program (IRP) Access Planning Policy, announced in NIH Guide Notice NOT-OD-25-062 in January 2025 and phased in for license applications submitted on or after the October 1 effective date. For technology transfer offices that negotiate sublicenses or collaboration terms involving NIH-owned IP, or that simply track how federal licensing norms evolve, this is a real change in what a complete license application now looks like – not a proposal still working through rulemaking.
What triggered the policy
The Access Planning Policy sits in the same policy lineage as longstanding public debate over the price and availability of medicines and devices developed with taxpayer support, and it follows years of scrutiny – from Congress, the Government Accountability Office, and outside advocacy groups – over whether Bayh-Dole Act-era licensing tools like march-in rights and reasonable-pricing clauses were being used to ensure inventions built on public funding actually reach patients on reasonable terms. NIH’s stated rationale is narrower and more procedural than a pricing mandate: the agency wants licensees to articulate, up front, a concrete plan for affordability, availability, acceptability, and sustainability of access – rather than leaving those questions unaddressed until a product nears market and access disputes surface after the fact.
Who it actually applies to – NIH-owned, not just NIH-funded
This is the distinction tech-transfer offices need to get right, because it is easy to conflate with the much broader universe of NIH grant-funded inventions. The Access Planning Policy applies specifically to commercial patent licenses for inventions where the U.S. government holds the patent, arising from research conducted by NIH’s own employees in its Intramural Research Program – the in-house laboratories at NIH and its institutes, not extramural grantee institutions. It covers exclusive, co-exclusive, partially exclusive, and non-exclusive license applications and the licenses ultimately granted on that intramural, NIH-owned IP.
It does not, as of this writing, apply to the far larger category of inventions made by university and research-institution faculty, postdocs, and staff under NIH grants or cooperative agreements – the ordinary case governed by the Bayh-Dole framework, where the university (not NIH) owns the resulting patent and controls licensing subject to Bayh-Dole’s own march-in and preference-for-U.S.-industry provisions. A university tech-transfer office negotiating a license to its own NIH-funded invention is not, on that basis alone, required to submit an NIH access plan. The policy reaches an institution only when the underlying patent itself is federally owned through NIH intramural research – for example, a university or company licensing an NIH-owned diagnostic, therapeutic, or research tool discovered in an NIH lab, or negotiating a Cooperative Research and Development Agreement (CRADA) with an NIH institute that leads to a follow-on commercial license.
What an access plan has to contain
NIH’s implementation guidance describes the access plan as a structured narrative rather than a fixed pricing commitment. Applicants are expected to address, at minimum:
- A description of the licensed product or products and the patient population(s) they are intended to serve;
- The tools, facilities, manufacturing capacity, or other resources the applicant will use to bring the product to that population;
- Concrete strategies for promoting access along four stated dimensions – affordability, availability, acceptability, and sustainability – to the extent those can be advanced on commercially reasonable terms.
Importantly, NIH has been explicit that the policy does not dictate specific pricing formulas, price caps, or other prescribed actions – it requires applicants to commit to a plan, with NIH’s implementation guidance offering dozens of non-binding illustrative examples of what access commitments can look like, precisely so applicants retain flexibility in how they satisfy the requirement. Access plans become part of the resulting license agreement, and NIH has indicated it may publish non-confidential versions of accepted plans, generally once a licensed product nears or receives regulatory approval, subject to the agency’s discretion over what is released. A waiver process exists for applicants who can show that access planning is not commercially feasible for a given license.
Effective date and transition
The policy was announced via NIH Guide Notice NOT-OD-25-062 in January 2025 and became operative for patent license applications submitted to NIH on or after October 1, 2025. NIH’s Office of Science Policy issued additional implementation guidance ahead of that date to clarify scope and documentation expectations. Tech-transfer offices should treat this as a hard cutover for new applications rather than a rolling or negotiated transition: an application submitted after October 1, 2025 for a license within scope is expected to include an access plan as a matter of course, not as an optional attachment NIH may or may not request.
What this means for university and institution tech-transfer offices
For most U.S. university and hospital tech-transfer offices, the direct hit rate is low – the majority of licensing activity involves institution-owned IP arising from NIH-funded (not NIH-owned) research, which sits outside this policy’s current scope. But the practical touchpoints are real and worth building into standard practice:
- CRADAs and other NIH intramural collaborations. Any institution that partners with an NIH institute or center under a CRADA, and whose collaboration produces or leads to a commercial license on the resulting NIH-owned IP, should expect an access plan to be part of that license negotiation going forward.
- In-licensing from NIH. University spinouts or established companies seeking to in-license an NIH-owned patent – a diagnostic platform, a research reagent, a therapeutic candidate discovered intramurally – now need to budget time and cross-functional input (regulatory, market access, manufacturing) to prepare a credible access plan as part of the application, not just the standard financial and diligence terms.
- Sublicensing chains. Where a university or company holds a master license to NIH-owned IP and sublicenses it downstream, the access-planning obligations attached to the head license may need to be reflected or referenced in sublicense terms – this is a due-diligence point worth flagging in any deal involving NIH-origin technology in the chain of title.
- Distinguishing scope in negotiations. Because the policy is easy to over-apply by analogy, tech-transfer offices should be precise in due diligence and in counterparty conversations about whether a given patent is actually NIH-owned (intramural) versus institution-owned-but-NIH-funded (extramural) – only the former currently triggers the requirement.
Whether a comparable access-planning obligation is extended to extramural, university-owned inventions arising from NIH grants remains an open policy question and is not currently in effect – tech-transfer offices should not assume the current intramural-only scope is permanent, and should watch for future NIH guidance if that boundary shifts.
Related reading
See CASRAI’s guides to 37 CFR 401: Bayh-Dole Implementing Regulations Explained, Bayh-Dole March-In Rights: What They Mean for University Tech Transfer, How Tech Transfer Offices Evaluate and Price a License, and iEdison: Invention Reporting and Utilization Reports for the broader federal invention-reporting and licensing framework this policy sits within.
